MNKD MannKind Corporation

1.68
-0.03  -2%
Previous Close 1.71
Open 1.71
Price To Book -1.3
Market Cap 268123923
Shares 159,597,573
Volume 1,316,528
Short Ratio
Av. Daily Volume 2,170,666

SEC filingsSee all SEC filings

  1. 8-K - Current report 181214063
  2. CT ORDER - Confidential treatment order 181210285
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152100
  4. 8-K - Current report 181152077
  5. 8-K - Current report 181124876

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved June 27, 2014.
AFREZZA
Type 1/2 diabetes
Phase 1 trial completion announced June 7, 2018.
Treprostinil Technosphere
Pulmonary Arterial Hypertension (PAH)

Latest News

  1. MNKD: Zacks SCR Initiates Coverage of MannKind With $4.25/share Price Target
  2. Biotech Stocks Beating the Market
  3. MannKind Appoints Christine Mundkur to its Board of Directors
  4. Analysts: Why United Therapeutics has had a streak of licensing deals
  5. Edited Transcript of MNKD earnings conference call or presentation 1-Nov-18 1:00pm GMT
  6. MannKind: 3Q Earnings Snapshot
  7. MannKind Corporation Reports 2018 Third Quarter Financial Results
  8. United Therapeutics Corp (UTHR) Q3 2018 Earnings Conference Call Transcript
  9. MannKind Corporation to Hold 2018 Third Quarter Financial Results Conference Call on November 1, 2018
  10. Research Report Identifies Cato, Roadrunner Transportation, Talend S.A, Vi, MannKind, and Acceleron Pharma with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  11. Today’s Research Reports on Stocks to Watch: Altimmune and MannKind
  12. Why MannKind Corp. Soared 16.4% Tuesday
  13. United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
  14. United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
  15. Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity
  16. Here's What Sent MannKind Corporation Soaring 66.4% in September
  17. MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
  18. MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes
  19. MannKind Stock History
  20. MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients

SEC Filings

  1. 8-K - Current report 181214063
  2. CT ORDER - Confidential treatment order 181210285
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 181152100
  4. 8-K - Current report 181152077
  5. 8-K - Current report 181124876
  6. 8-K - Current report 181089412
  7. 8-K - Current report 181056708
  8. 8-K - Current report 181054878
  9. S-8 - Securities to be offered to employees in employee benefit plans 18998595
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 18988291